ArticleBioconjugate chemistry
Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.
Article in Bioconjugate chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 130 citations in OpenAlex.
- His-Tag-Aptamer-Liposome-Conjugates as a Multipurpose Tool for Recombinant Protein Screening and Protein-Based Bioassays.Analytical chemistry · 2026Article
- Novel nanoliposomes for targeted codelivery of three anticancer agents against head and neck squamous cell carcinoma.Research in pharmaceutical sciences · 2026Article
- Nanobiomaterial-enabled boron delivery systems and innovative strategies for revolutionizing BNCT.Theranostics · 2026Review
- Review
- Boron Neutron Capture Therapy: Current Status and Challenges.Frontiers in oncology · 2022Review
- Specific Targeting of PEGylated Liposomal Doxorubicin (DoxilMolecules (Basel, Switzerland) · 2020Article
- Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management.Pharmaceutics · 2020Review
- Boron delivery agents for neutron capture therapy of cancer.Cancer communications (London, England) · 2018Review
- Chemical Reactive Anchoring Lipids with Different Performance for Cell Surface Re-engineering Application.ACS omega · 2018Article
- Enhanced Antitumor Effects of Epidermal Growth Factor Receptor Targetable Cetuximab-Conjugated Polymeric Micelles for Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2018Article
- The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Frontiers in immunology · 2018Review
- EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.Molecular pharmaceutics · 2017Article
- Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2/KDR antibody.International journal of nanomedicine · 2017Article
- Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells.Anti-cancer agents in medicinal chemistry · 2017Article
- Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.Anti-cancer agents in medicinal chemistry · 2017Article
- Cancer active targeting by nanoparticles: a comprehensive review of literature.Journal of cancer research and clinical oncology · 2015Review
- Liposome surface functionalization based on different anchoring lipids via Staudinger ligation.Organic & biomolecular chemistry · 2014Article
- Targeting cancer using cholesterol conjugates.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Review
- Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer.Radiation oncology (London, England) · 2012Review
- Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery.International journal of nanomedicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The objective of the present study was to construct epidermal growth factor receptor (EGFR) targeting cetuximab-immunoliposomes (ILs) for targeted delivery of boron compounds to EGFR(+) glioma cells for neutron capture therapy. The ILs were synthesized by using a novel cholesterol-based membrane anchor, maleimido-PEG-cholesterol (Mal-PEG-Chol), to incorporate cetuximab into liposomes by either surface conjugation or a post-insertion method. For post-insertion, the transfer efficiency of MAb conjugates from micelles to liposome was examined at varying temperatures, mPEG2000-DSPE ratios, and micelle-to-liposome lipid ratios. Following this, the cetuximab-ILs were evaluated for targeted delivery of the encapsulated boron anion, dodecahydro-closo-dodecaborate (2-) (B12H122-), to human EGFR gene transfected F98EGFR glioma cells as potential delivery agents for boron neutron capture therapy (BNCT). In addition, cellular uptake of cetuximab-ILs, encapsulating a fluorescence dye, was analyzed by confocal fluorescence microscopy and flow cytometry, and boron content was quantified by ICP-MS. Much greater ( approximately 8-fold) cellular uptake of boron was obtained using cetuximab-ILs in EGFR(+) F98EGFR compared with nontargeted human IgG-ILs. On the basis of these observations, we have concluded that cholesterol can serve as an effective anchor for MAb in liposomes, and cetuximab-ILs are potentially useful delivery vehicles for BNCT of gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.